Contents, Vol. 52, 1994
Tatsuo Igarashi, H.R.F. Plancke, Luigi Frati, Hirojiroh Sumi, Shotaro Sato, S. Colagrande, Laura Iolanda Pastore, Satoshi Kitahara(National Defense Medical College), Y Shichijo, Paola Gazzaniga(Sapienza University of Rome), Jun Shimazaki, A. Dami, Takashi Morita(Chubu University), Shino Muakami, Tomoyuki Ishibe, J. Raßler, Douglas G. Mack, Takeshi Komeyama, W. Dorschner, Vittorio Manzari, Hiroaki Shiina(Shimane University), Takako Koizumi, Akihiko Hatano, Maria Napolitano, F. Melone, Angela Gradilone(Sapienza University of Rome), Mauro Cervigni, Hans Peter Schmid(Karlsruhe Institute of Technology), G.B. Muraro, Masayuki Takeda(Kindai University), Makoto Tamaki, Tsuguru Usui, J. Frick, U Farina, Masao Ando, Anna Maria Aglianò, Shigeo Isaka, Muta M. Issa, Hitoshi Takahashi, Hiroyuki Oshima, Kazunori Kihara(Tokyo Medical and Dental University), Thomas A. Stamey(Stanford Medicine), Toshiki Tsutsui, J.‐U. Stolzenburg, Takeshi Matsumura(Kanazawa University), Kazuhiro Ishizaka, Osamu Matsuzaki
Cited by 0
Related Papers
Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer
|JAMA Oncology|2017|1k
Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
|Science Translational Medicine|2011|670
Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment
|Annals of Oncology|2017|294
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper
|Critical Reviews in Oncology/Hematology|2018|268
Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in <i>EGFR</i> Mutation–Positive Non–Small Cell Lung Cancer
|Clinical Cancer Research|2020|244